برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Plenvu (polyethylene glycol 3350 with electrolytes) for Oral Solution Date of Approval: May 4, 2018 Company: Salix Pharmaceuticals, Inc. Treatment for: Bowel Preparation Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride) is a lower-volume, polyethylene glycol based osmotic laxative indicated for cleansing of the colon (bowel preparation) prior to colonoscopy. https://t.me/ppdprogram

➡️Akynzeo for Injection (fosnetupitant and palonosetron) Date of Approval: April 19, 2018 Company: Helsinn Treatment for: Nausea/Vomiting, Chemotherapy Induced Akynzeo for Injection (fosnetupitant and palonosetron) is a substance P/neurokinin-1 (NK-1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist combination indicated for use with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV). https://t.me/ppdprogram

➡️ZTlido (lidocaine) Patch - formerly Ztilido Date of Approval: February 28, 2018 Company: Scilex Pharmaceuticals, Inc. Treatment for: Postherpetic Neuralgia ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia. https://t.me/ppdprogram

➡️Firvanq (vancomycin hydrochloride) for Oral Solution Date of Approval: January 26, 2018 Company: CutisPharma Treatment for: Clostridium Difficile Associated Diarrhea; Enterocolitis Firvanq (vancomycin hydrochloride) is an oral solution formulation of an approved tricyclic glycopeptide antibiotic for the treatment of Clostridium difficile associated diarrhea and Staphylococcus aureus enterocolitis. https://t.me/ppdprogram

➡️Dayvigo (lemborexant) Tablets Date of Approval: December 20, 2019 Company: Eisai Co., Ltd. Treatment for: Insomnia Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia. https://t.me/ppdprogram

➡️Caplyta (lumateperone) Capsules Date of Approval: December 20, 2019 Company: Intra-Cellular Therapies, Inc. Treatment for: Schizophrenia, Bipolar Disorder Caplyta (lumateperone) is an atypical antipsychotic for the treatment of schizophrenia and bipolar depression. https://t.me/ppdprogram

➡️Arazlo (tazarotene) Lotion Date of Approval: December 18, 2019 Company: Bausch Health Companies Inc. Treatment for: Acne Arazlo (tazarotene) is a lotion formulation of the approved retinoid tazarotene for the topical treatment of acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Nouress (cysteine hydrochloride) Injection Date of Approval: December 13, 2019 Company: Avadel Pharmaceuticals plc Treatment for: Total Parenteral Nutrition Nouress (cysteine hydrochloride) is a sulfur-containing amino acid indicated for use as an additive to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral nutrition. https://t.me/ppdprogram

➡️Oxbryta (voxelotor) Tablets Date of Approval: November 25, 2019 Company: Global Blood Therapeutics, Inc. Treatment for: Anemia, Sickle Cell Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD). https://t.me/ppdprogram

➡️Xcopri (cenobamate) Tablets Date of Approval: November 21, 2019 Company: SK Life Science, Inc. Treatment for: Seizures Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients. https://t.me/ppdprogram

➡️Givlaari (givosiran) Injection Date of Approval: November 20, 2019 Company: Alnylam Pharmaceuticals, Inc. Treatment for: Acute Hepatic Porphyria Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA (siRNA) indicated for the treatment of adults with acute hepatic porphyria (AHP). https://t.me/ppdprogram

➡️Fetroja (cefiderocol) Injection Date of Approval: November 14, 2019 Company: Shionogi & Co., Ltd. Treatment for: Complicated Urinary Tract Infections; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia Fetroja (cefiderocol) is a siderophore cephalosporin indicated for the treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms. https://t.me/ppdprogram

➡️Reblozyl (luspatercept-aamt) for Injection Date of Approval: November 8, 2019 Company: Celgene Corporation Treatment for: Anemia in Beta-Thalassemia; Anemia in Lower-Risk Myelodysplastic Syndromes Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for the treatment of: Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia. https://t.me/ppdprogram

➡️Ziextenzo (pegfilgrastim-bmez) Injection Date of Approval: November 4, 2019 Company: Sandoz Treatment for: Neutropenia Associated with Chemotherapy Ziextenzo (pegfilgrastim-bmez) is a PEGylated growth colony-stimulating factor biosimilar to Neulasta (pegfilgrastim) used to reduce the incidence of febrile neutropenia in patients treated with chemotherapy. https://t.me/ppdprogram

➡️Talicia (amoxicillin, omeprazole and rifabutin) Delayed-Release Capsules Date of Approval: November 4, 2019 Company: RedHill Biopharma Ltd. Treatment for: Helicobacter Pylori Infection Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a fixed-dose combination of two antibiotics, (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) for the treatment of Helicobacter pylori (H. pylori) infection. https://t.me/ppdprogram

➡️Biorphen (phenylephrine hydrochloride) Injection Date of Approval: October 21, 2019 Company: Eton Pharmaceuticals, Inc. Treatment for: Hypotension Biorphen (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension during anesthesia. https://t.me/ppdprogram

➡️Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Tablets Date of Approval: October 21, 2019 Company: Vertex Pharmaceuticals Incorporated Treatment for: Cystic Fibrosis Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data. https://t.me/ppdprogram

➡️Amzeeq (minocycline) Topical Foam Date of Approval: October 18, 2019 Company: Foamix Pharmaceuticals Treatment for: Acne Amzeeq (minocycline) is a topical foam formulation of the approved tetracycline drug minocycline indicated for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Secuado (asenapine) Transdermal System Date of Approval: October 11, 2019 Company: Noven Pharmaceuticals, Inc. Treatment for: Schizophrenia Secuado (asenapine) is a transdermal atypical antipsychotic formulation indicated for the treatment of adults with schizophrenia. https://t.me/ppdprogram

➡️Reyvow (lasmiditan) Tablets Date of Approval: October 11, 2019 Company: Eli Lilly and Company Treatment for: Migraine Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram